SETTING: Tygerberg Children's Hospital, Cape Town, South Africa. OBJECTIVE: To determine the prevalence and trend of drug resistance and human immunodeficiency virus (HIV) co-infection among children with culture-confirmed tuberculosis (TB). METHOD: Prospective surveillance from March 2007 to February 2009, compared to three previous surveys (1994-1998, 2003-2005, 2005-2007). Drug susceptibility testing (DST) against isoniazid (INH) and rifampicin (RMP) was performed using genotypic and phenotypic testing. If multidrug-resistant TB (MDR-TB) was detected, further DST against ethambutol (EMB) and second-line drugs was performed. RESULTS: A total of 294 children with a median age of 26 months (range 3 days-13 years) were diagnosed with culture-confirmed TB. DST results were available for 292 (99.3%); 41 (14%) were INH-resistant, including 26 (8.9%) with MDR-TB. Four children (1.4%) had RMP monoresistance. EMB resistance was present in 12/24 (50%) MDR-TB cases tested. Two isolates were resistant to ofloxacin; none had extensively drug-resistant TB. Of those tested, 29% (63/217) were HIV-infected. Any resistance to RMP increased between 1994 and 2009 (P < 0.001), as did RMP monoresistance (P = 0.009) and MDR-TB (P < 0.001). Sensitivity was 87.5% and specificity 100% for genotypic compared to phenotypic testing for INH resistance. CONCLUSIONS: RMP, and consequently multidrug, resistance is increasing among children with TB in this setting. EMB resistance is common among children with resistance to RMP and INH.
SETTING: Tygerberg Children's Hospital, Cape Town, South Africa. OBJECTIVE: To determine the prevalence and trend of drug resistance and human immunodeficiency virus (HIV) co-infection among children with culture-confirmed tuberculosis (TB). METHOD: Prospective surveillance from March 2007 to February 2009, compared to three previous surveys (1994-1998, 2003-2005, 2005-2007). Drug susceptibility testing (DST) against isoniazid (INH) and rifampicin (RMP) was performed using genotypic and phenotypic testing. If multidrug-resistant TB (MDR-TB) was detected, further DST against ethambutol (EMB) and second-line drugs was performed. RESULTS: A total of 294 children with a median age of 26 months (range 3 days-13 years) were diagnosed with culture-confirmed TB. DST results were available for 292 (99.3%); 41 (14%) were INH-resistant, including 26 (8.9%) with MDR-TB. Four children (1.4%) had RMP monoresistance. EMB resistance was present in 12/24 (50%) MDR-TB cases tested. Two isolates were resistant to ofloxacin; none had extensively drug-resistant TB. Of those tested, 29% (63/217) were HIV-infected. Any resistance to RMP increased between 1994 and 2009 (P < 0.001), as did RMP monoresistance (P = 0.009) and MDR-TB (P < 0.001). Sensitivity was 87.5% and specificity 100% for genotypic compared to phenotypic testing for INH resistance. CONCLUSIONS:RMP, and consequently multidrug, resistance is increasing among children with TB in this setting. EMB resistance is common among children with resistance to RMP and INH.
Authors: P C Rose; H S Schaaf; K du Preez; J A Seddon; A J Garcia-Prats; K Zimri; R Dunbar; A C Hesseling Journal: Public Health Action Date: 2013-09-21
Authors: Ben J Marais; Charmaine K Mlambo; Nalin Rastogi; Thierry Zozio; Adriano G Duse; Thomas C Victor; Else Marais; Robin M Warren Journal: J Clin Microbiol Date: 2013-04-03 Impact factor: 5.948
Authors: Paolo Denti; Anneke C Hesseling; Louvina E van der Laan; Anthony J Garcia-Prats; H Simon Schaaf; Tjokosela Tikiso; Lubbe Wiesner; Mine de Kock; Jana Winckler; Jennifer Norman; Helen McIlleron Journal: Antimicrob Agents Chemother Date: 2018-01-25 Impact factor: 5.191
Authors: S Thee; A J Garcia-Prats; H M McIlleron; L Wiesner; S Castel; J Norman; H R Draper; P L van der Merwe; A C Hesseling; H S Schaaf Journal: Antimicrob Agents Chemother Date: 2014-02-18 Impact factor: 5.191
Authors: B K Moore; E Anyalechi; M van der Walt; S Smith; L Erasmus; J Lancaster; S Morris; N Ndjeka; J Ershova; N Ismail; D Burton; H Menzies Journal: Int J Tuberc Lung Dis Date: 2015-06 Impact factor: 2.373
Authors: Eric W Hall; Sapna B Morris; Brittany K Moore; Linda Erasmus; Ronel Odendaal; Heather Menzies; Martie van der Walt; Sarah E Smith Journal: Pediatr Infect Dis J Date: 2017-12 Impact factor: 2.129
Authors: K Schopfer; H L Rieder; J F Steinlin-Schopfer; D van Soolingen; T Bodmer; Y Chantana; P Studer; D Laurent; M Zwahlen; B Richner Journal: Epidemiol Infect Date: 2014-07-22 Impact factor: 4.434